Lack of significant inhibitory effects of a plant lignan tracheloside on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary carcinogenesis in female Sprague-Dawley rats.
Tracheloside, one of the plant lignans which can be extracted from the debris after safflower oil is produced from the seeds of Carthamus tinctorious, is an analogue of another plant lignan, arctiin, the side-chain C-2 of the five-membered ring being changed from a hydrogen to a hydroxyl group. We have already demonstrated that arctiin has chemopreventive effect on mammary carcinogenesis. Therefore, chemopreventive effects of tracheloside on the initiation or post-initiation period of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary carcinogenesis in female rats were examined. For initiation, female Sprague-Dawley (SD) rats at the 6 weeks of age were given intragastric administrations of 100 mg/kg body weight of PhIP once a week for 8 weeks. The animals were treated with 0.2 or 0.02% tracheloside during or after this carcinogen exposure. Control rats were fed basal diet with PhIP initiation or 0.2% tracheloside or basal diet alone without initiation throughout the experimental period. All surviving animals were necropsied at the week 52 of administration. There were no clear treatment-related changes with statistical significance in all parameters for mammary carcinomas measured in this experiment. These results indicate that tracheloside may not exert significant effects on PhIP-induced mammary carcinogenesis at least under the present experiment condition.
Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Yasuki
Y
Kitamura
Megumi
M
Yamagishi
Kazushi
K
Okazaki
Hwa-Young
HY
Son
Takayoshi
T
Imazawa
Akiyoshi
A
Nishikawa
Toshio
T
Iwata
Yoshie
Y
Yamauchi
Masaaki
M
Kasai
Kentaro
K
Tsutsumi
Masao
M
Hirose
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology; D002273:Carcinogens; D005260:Female; D005960:Glucosides / Q000494:pharmacology*; D007093:Imidazoles; D017705:Lignans / Q000494:pharmacology; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D005960:Glucosides; D007093:Imidazoles; D017705:Lignans; C079169:tracheloside; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; D015107:4-Butyrolactone